Skip to main content

Table 3 Details of the chemotherapy and radiotherapy received by the patients

From: Epidemiology of early infections and predictors of mortality after autologous hematopoietic stem-cell transplantation among multiple myeloma, Hodgkin, and non-Hodgkin lymphoma: the first experience from Palestine

Previous therapy

Type of HM

Chi-square/Fisher’s exact test

p-value

NHL

HL

MM

n

%

n

%

n

%

Radiotherapy

 No

20

13.8

47

32.4

62

42.8

0.2

0.720

 Yes

3

2.1

6

4.1

7

4.8

Bortezomib

 No

23

15.9

53

36.6

0

0.0

145.0

< 0.001

 Yes

0

0.0

0

0.0

69

47.6

ABVD

 No

23

15.9

0

0.0

69

47.6

145.0

< 0.001

 Yes

0

0.0

53

36.6

0

0.0

CHOP

 No

0

0.0

53

36.6

69

47.6

145.0

< 0.001

 Yes

23

15.9

0

0.0

0

0.0

ICE

 No

19

13.1

47

32.4

69

47.6

10.3

0.002

 Yes

4

2.8

6

4.1

0

0.0

IGEV

 No

14

9.7

26

17.9

69

47.6

44.7

< 0.001

 Yes

9

6.2

27

18.6

0

0.0

DHAP

 No

10

6.9

29

20.0

69

47.6

46.2

< 0.001

 Yes

13

9.0

24

16.6

0

0.0

CVP

 No

22

15.2

53

36.6

69

47.6

3.3

0.159

 Yes

1

0.7

0

0.0

0

0.0

GDP

 No

23

15.9

47

32.4

69

47.6

8.8

0.005

 Yes

0

0.0

6

4.1

0

0.0

Conditioning

 LEAM

16

11.0

37

25.5

0

0.0

100.6

< 0.001

 BEAM

7

4.8

11

7.6

0

0.0

 TEAM

0

0.0

1

0.7

0

0.0

 Melphalan

0

0.0

4

2.8

69

47.6

  1. HL Hodgkin’s lymphoma, HM hematological malignancy, NHL non-Hodgkin’s lymphoma, MM multiple myeloma